At a glance
ClinicalIndex Comparison Record- ✓Completed platinum agent, taxane, vinca alkaloid, or bortezomib therapy at least 3 months prior to registration
- ✓Clinical diagnosis of bilateral CIPN with abnormal sensory symptoms in feet or legs (pain, numbness, tingling, cramping)
- ✓At least 1 non-painful CIPN symptom in lower limbs (tingling, burning, or numbness)
- ✓At least 2 symptoms in lower limbs rated ≥4/10 on 0-10 scale (hot/burning pain, sharp/shooting pain, numbness, tingling, or cramping)
- ✕Pre-existing neuropathy of any cause prior to chemotherapy or history of numbness, tingling, or neuropathic pain before chemotherapy
- ✕Unilateral CIPN symptoms (symptoms on predominantly only one side of body)
- ✕Currently using TENS device for any other reason
- ✕Currently taking or taken in past 3 months medications known to cause neuropathy in significant portion of patients
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-Induced Peripheral Neuropathy: A Phase II Clinical Trial
In Brief
A clinical study evaluating Placebo Administration, Questionnaire Administration, and 1 other intervention for Chemotherapy-Induced Peripheral Neuropathy. Completed, enrolled 151 participants across 15 sites.
Detailed Summary
This phase II trial studies the effects of transcutaneous electrical nerve stimulation (TENS) for the treatment of peripheral neuropathy caused by chemotherapy, often called chemotherapy-induced peripheral neuropathy (CIPN). Peripheral neuropathy refers to the conditions that result when nerves that carry messages to and from the brain and spinal cord from and to the rest of the body are damaged or diseased. The TENS device emits high frequency electrical stimulation through the skin and may provide relief from chronic pain.
Study Details
Timeline
Interventions
Wear placebo TENS device
Ancillary studies
Wear active TENS device